SLC5A2 and chronic kidney disease: A large meta-analysis of placebo-controlled trials indicates that the use of SGLT2 inhibitors modifies the risk of CKD progression and acute kidney injury, not only in patients with type 2 DM at high cardiovascular risk but also in patients with CKD or heart failure irrespective of DM [375].